In recent years, there have been dramatic advances in the treatment of lung adenocarcinoma because of the development of therapies targeting driver oncogene alterations, for example, drugs targeting the epidermal growth factor receptor (EGFR) mutation or the anaplastic lymphoma kinase (ALK) fusion [1, 2]. The gene discussed is ALK; the disease is lung adenocarcinoma.